Cargando…

Should benefit–risk assessment have its own drug “label”?

Many consumers and clinicians incorrectly believe that the Food and Drug Administration (FDA) approval of a new therapeutic implies that its benefits have been proven to exceed its harms. While the FDA could require proof that benefits exceed harms prior to approval, it has been argued that this app...

Descripción completa

Detalles Bibliográficos
Autor principal: Braithwaite, R Scott
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3163936/
https://www.ncbi.nlm.nih.gov/pubmed/21904466
http://dx.doi.org/10.2147/DHPS.S21927
_version_ 1782210998621437952
author Braithwaite, R Scott
author_facet Braithwaite, R Scott
author_sort Braithwaite, R Scott
collection PubMed
description Many consumers and clinicians incorrectly believe that the Food and Drug Administration (FDA) approval of a new therapeutic implies that its benefits have been proven to exceed its harms. While the FDA could require proof that benefits exceed harms prior to approval, it has been argued that this approach would be infeasible because of prohibitively large sample sizes. One possible alternative would be for the FDA to supplement its standard “label” denoting “safe and effective” with a secondary “label” denoting benefits have been demonstrated to exceed harms, which would be granted only after sufficient post-marketing data had accumulated to prove that its benefits exceeded its harms. This secondary label would not necessarily be linked to marketing restrictions or other commercial prohibitions but, rather, would be only information for consumers and clinicians. Strengths, weaknesses, and feasibility challenges of this approach are discussed.
format Online
Article
Text
id pubmed-3163936
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-31639362011-09-08 Should benefit–risk assessment have its own drug “label”? Braithwaite, R Scott Drug Healthc Patient Saf Perspectives Many consumers and clinicians incorrectly believe that the Food and Drug Administration (FDA) approval of a new therapeutic implies that its benefits have been proven to exceed its harms. While the FDA could require proof that benefits exceed harms prior to approval, it has been argued that this approach would be infeasible because of prohibitively large sample sizes. One possible alternative would be for the FDA to supplement its standard “label” denoting “safe and effective” with a secondary “label” denoting benefits have been demonstrated to exceed harms, which would be granted only after sufficient post-marketing data had accumulated to prove that its benefits exceeded its harms. This secondary label would not necessarily be linked to marketing restrictions or other commercial prohibitions but, rather, would be only information for consumers and clinicians. Strengths, weaknesses, and feasibility challenges of this approach are discussed. Dove Medical Press 2011-08-03 /pmc/articles/PMC3163936/ /pubmed/21904466 http://dx.doi.org/10.2147/DHPS.S21927 Text en © 2011 Braithwaite, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Perspectives
Braithwaite, R Scott
Should benefit–risk assessment have its own drug “label”?
title Should benefit–risk assessment have its own drug “label”?
title_full Should benefit–risk assessment have its own drug “label”?
title_fullStr Should benefit–risk assessment have its own drug “label”?
title_full_unstemmed Should benefit–risk assessment have its own drug “label”?
title_short Should benefit–risk assessment have its own drug “label”?
title_sort should benefit–risk assessment have its own drug “label”?
topic Perspectives
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3163936/
https://www.ncbi.nlm.nih.gov/pubmed/21904466
http://dx.doi.org/10.2147/DHPS.S21927
work_keys_str_mv AT braithwaiterscott shouldbenefitriskassessmenthaveitsowndruglabel